No significant change in arterial stiffness in RA after 6 months and 1 year of rituximab treatment

Rheumatology (United Kingdom)

Volumn 51, Issue 6, 2012, Pages 1107-1111

  Mathieu, Sylvain ^a,b   Pereira, Bruno ^a,b   Dubost, Jean Jacques ^a,b   Lusson, Jean René ^a,b   Soubrier, Martin ^a,b  

^a SERVICE DE RHUMATOLOGIE   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

Arterial stiffness; Cardiovascular risk markers; Rheumatoid arthritis; Rituximab

Indexed keywords

HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHYLPREDNISOLONE; RITUXIMAB; TRIACYLGLYCEROL;

ADULT; ARTERIAL STIFFNESS; ARTICLE; ATHEROSCLEROSIS; AUGMENTATION INDEX; BLOOD PRESSURE; CARDIOVASCULAR RISK; FEMALE; HUMAN; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PULSE WAVE; RHEUMATOID ARTHRITIS;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; COMORBIDITY; FEMALE; HUMANS; LIPODYSTROPHY; MALE; MIDDLE AGED; RISK FACTORS; TIME FACTORS; VASCULAR STIFFNESS; VASCULITIS;

EID: 84861468047     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes006     Document Type: Article

References (20)

1. Meune C, TouzéE, Trinquart L et al. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology 2009;48:1309-13.
2. Aviña-Zubieta JA, Choi HK, Sadatsafavi M et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008;59:1690-7.
3. Solomon DH, Kremer J, Curtis JR et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 2010;69:1920-5.
4. Sattar N, McCarey DW, Capell H et al. Explaining how 'high-grade' systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003;108: 2957-63.
5. van Bussel BC, Schouten F, Henry RM et al. Endothelial dysfunction and low-grade inflammation are associated with greater arterial stiffness over a 6-year period. Hypertension 2011;58:588-95.
6. Verma S, Kuliszewski MA, Li SH et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 2004;109:2058-67.
7. Mäki-Petäjä KM, Wilkinson IB. Anti-inflammatory drugs and statins for arterial stiffness reduction. Curr Pharm Des 2009;15:290-303.
8. Mäki-Petäjä KM, Hall FC, Booth AD et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation 2006;114:1185-92.
9. Van Doormun S, McColl G, Jenkins A et al. Screening for atherosclerosis in patients with rheumatoid arthritis. Comparison of two in vivo tests of vascular function. Arthritis Rheum 2003;28:72-80.
10. Wong M, Toh L, Wilson A et al. Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease factors and inflammation. Arthritis Rheum 2003; 48:81-9.
11. Van Doornum S, McColl G, Wicks IP. Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis. Rheumatology 2005;44: 1428-32.
12. Cohen SB, Emery P, Greenwald MW et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806.
13. Ait-Oufella H, Herbin O, Bouaziz JD et al. B cell depletion reduces the development of atherosclerosis in mice. J Exp Med 2010;207:1579-87.
14. Gonzalez-Juanatey C, Llorca J, Vazquez-Rodriguez TR et al. Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor α blocker therapy. Arthritis Rheum 2008;59:1821-4.
15. Kerekes G, Soltész P, Dér H et al. Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin Rheumatol 2009;28:705-10.
16. Sandoo A, Toms T, Zanten JV et al. Short-term effects of rituximab on flow-mediated dilatation may be mediated by intravenous glucocorticoids: comment on the article by Gonzalez-Juanatey et al. Arthritis Rheum 2009;61:854-5.
17. Dass S, Rawstron AC, Vital EM et al. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 2008;58:2993-9.
18. Barnabe CCM, Martin BJ, Ghali WA. Systematic review and meta-analysis: anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res 2011;63:522-9.
19. Walldius G, Jungner I, Aastveit AH et al. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med 2004;42:1355-63.
20. Arts E, Jansen TL, Den Broeder A et al. Statins Inhibit the anti-rheumatic effects of rituximab in rheumatoid arthritis-results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) Registry. Abstract supplement. Arthritis Rheum 2010;62:S766.